- Global Pharma News & Resources

RGN-259: A TB4-based Sterile and Preservative-free Eye Drop, As a Novel Treatment for Dry Eye and Neurotrophic Keratitis (NK) - Global Emerging Insight and Market Forecast 2021-2030 -

DUBLIN--(BUSINESS WIRE)--The "RGN-259 - Emerging Insight and Market Forecast - 2030" report has been added to's offering.

RGN-259, a TB4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK), a persistent corneal defect caused by diabetes and herpes zoster virus, among other pathologies. RGN-259 has received orphan drug status from the U.S. FDA for the treatment of NK.

"RGN-259 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Persistent Epithelial Defect in 7 Major Markets. A detailed picture of the RGN-259 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.


RGN-259 represents a new approach to corneal healing, as there is currently no pharmaceutical agent that has shown corneal repair and anti-inflammatory properties. Preclinical studies have shown that TB4 promotes cell migration, increases cell-cell and cell-matrix contacts through increase laminin-5 production, and reduces both apoptosis and inflammation in the cornea.

RGN-259 Analytical Perspective

In-depth RGN-259 Market Assessment

This report provides a detailed market assessment of RGN-259 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

RGN-259 Clinical Assessment

The report provides the clinical trials information of RGN-259 covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

  • In the coming years, the market scenario for Persistent Epithelial Defect is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence RGN-259 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Persistent Epithelial Defect are giving market competition to RGN-259 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of RGN-259.
  • This in-depth analysis of the forecasted sales data of RGN-259 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the RGN-259.

Key Questions Answered

  • Which company is developing RGN-259 along with the phase of the clinical study?
  • What is the technology utilized in the development of RGN-259?
  • What is the product type, route of administration and mechanism of action of RGN-259?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RGN-259 development?
  • What are the key designations that have been granted to RGN-259?
  • What is the forecasted market scenario of RGN-259?
  • What is the history of RGN-259 and what is its future?
  • What is the forecasted sales of RGN-259 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to RGN-259?
  • Which are the late-stage emerging therapies under development for the treatment of the Persistent Epithelial Defect?

Scope of the Report

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with an expiry timeline around RGN-259.
  • The report contains forecasted sales for RGN-259 till 2030.
  • Comprehensive coverage of the mid-stage emerging therapies (Phase II) for Persistent Epithelial Defect.
  • The report also features the SWOT analysis with analyst insights and key findings of RGN-259.

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 10-Mar-2021